← Signal Board

Kiniksa Pharmaceuticals Class A financial statements

키닉사 파머슈티컬스 인터내셔널NASDAQ:KNSA · Nasdaq · Healthcare · sector #17
$77.96+1.13%
2026-10-07 close

Kiniksa Pharmaceuticals Class A's published financial data is dated 2026-10-04. 2024 revenue was $423M. 2024 operating profit was −$46M.

Reported results

Financial safety

Reference indicatorAs of 2024
Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 2.40
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
2.40
Beneish M-Score
-2.39

No statistical flag

Sloan accrual
-11.86%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROANot passed
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업외손익 급변 (영업이익 대비 81% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-10.8%
Interest coverage
-18.8x
Return on equity (ROE)
-9.9%

Operating margin −5pp

Operating loss
Interest coverageBase -18.8x adverse case -27.6x
Return on equity (ROE)Base -9.9% adverse case -15.8%

Revenue −15%

Interest coverage risk
Interest coverageBase -18.8x adverse case -16x
Return on equity (ROE)Base -9.9% adverse case -9.4%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -18.8x adverse case -8.7x
Return on equity (ROE)Base -9.9% adverse case -11.6%

Interest coverage limit

Already below the limit by 11.4pp

Interest coverage limit at an operating margin of 0.6%

Interest expense coverage threshold

Kiniksa Pharmaceuticals Class A notifications

Quantus Signal · live data · not investment advice · Privacy Policy